2021
Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA.
Frontiers in oncology
•Christopher R. Cogle, M.D. is a physician and scientist with research focus on cancer and health policy. In his early career Dr. Cogle discovered that blood stem cells make blood vessels and used that biology to invent new therapeutics and diagnostics for people with cancer and heart disease. In his mid career, as a Leukemia & Lymphoma Society Scholar in Clinical Research, he translated laboratory research discoveries into investigator-initiated clinical trials. Dr. Cogle has also made major discoveries in cancer epidemiology and was elected to lead Florida’s cancer prevention and control efforts at the state level, producing the Florida Cancer Plan, leading statewide campaigns for improved cancer prevention and control, and advising the Florida Legislature, Florida Secretary of ÍøºìºÚÁÏ, and Florida Governor on evidence-based strategies to reduce the state's cancer burden. In 2020, Dr. Cogle was selected by the National Academy of Medicine as an Emerging Leader in ÍøºìºÚÁÏ and Medicine Scholar. In 2021, Dr.Cogle founded the Florida ÍøºìºÚÁÏ Policy Leadership Academy at the Bob Graham Center for Public Service. His academy team of faculty trains Florida's community leaders in promoting health and preventing disease and disease progression for Florida's 21 million residents and 100 million visitors. In 2023, he was selected by the Milbank Memorial Foundation as a state health policy fellow.
172 publications
2021
Frontiers in oncology
•2021
International journal of laboratory hematology
•2021
Cancers
•2021
ÍøºìºÚÁÏcare
•2020
ÍøºìºÚÁÏcare
•